As the globe faces a rise in antibiotic-resistant bacteria—making traditional ... now better known for its applications in medicine and biotechnology. CRISPR systems in general act as "molecular ...

A leading expert voices highly cautious optimism over the very few steps taken today that could help tackle the threat to ...

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma ...

When I left Idenix (an antiviral biotech) in 2005, had no idea what I would be doing next. We sold our house in the Boston area and moved to France while I tried to formulate a plan. Shortly after our ...

Today, antibiotics are the third largest-selling class of drugs, with a worldwide annual market estimated between $7 and $22 billion. More than 150 antibacterial drugs have now been approved in ...

Unable to generate reasonable returns, most large pharmaceutical companies have stopped antibiotic R&D. At the same time, private investors have largely abandoned smaller biotech companies in this ...

While most pharma companies have exited the antibiotics area, Japanese drugmaker Shionogi has stuck with it and has just expanded its pipeline with a deal to buy US biotech Qpex Biopharma ...

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new treatments in an era of rising antibiotic resistance.

The push for antibiotics to fight fast-evolving superbugs is snagging on a broken business model. Six startups have won Food and Drug Administration approval for new antibiotics since 2017.

Finding #1: Biotech VCs view their investments as central to bringing new drugs to market and are aware of the significant benefits and risks associated with their investments.

Whatever you do, don’t ask for an antibiotic: Research suggests that doctors are more likely to prescribe the medication when they perceive patients expect it. Ask for the shortest course. It ...